Abstract
Background Biallelic PRKN mutation carriers with Parkinson’s disease (PD) typically have an earlier disease onset, slow disease progression and, often, different neuropathology compared to sporadic PD patients. However, the role of heterozygous PRKN variants in the risk of PD is controversial.
Objectives We aimed to examine the association between heterozygous PRKN variants, including single nucleotide variants and copy-number variations, and PD.
Methods We fully sequenced PRKN in 2,809 PD patients and 3,629 healthy controls, including 1,965 late onset (63.97±7.79 years, 63% men) and 553 early onset PD patients (43.33±6.59 years, 68% men). PRKN was sequenced using targeted next-generation sequencing with molecular inversion probes. Copy-number variations were identified using a combination of multiplex ligation-dependent probe amplification and ExomeDepth. To examine whether rare heterozygous single nucleotide variants and copy-number variations in PRKN are associated with PD risk and onset, we used optimized sequence kernel association tests and regression models.
Results We did not find any associations between all types of PRKN variants and risk of PD. Pathogenic and likely-pathogenic heterozygous single nucleotide variants and copy-number variations were less common among PD patients (1.52%) than among controls (1.8%, false discovery rate-corrected p=0.55). No associations with age at onset and in stratified analyses were found.
Conclusions Heterozygous single nucleotide variants and copy-number variations in PRKN are not associated with Parkinson’s disease. Molecular inversion probes allow for rapid and cost-effective detection of all types of PRKN variants, which may be useful for pre-trial screening and for clinical and basic science studies specifically targeting PRKN patients.
Competing Interest Statement
Dr. Fahn received consulting fees/honoraria for board membership from Retrophin Inc., Sun Pharma Advanced Research Co., LTD and Kashiv Pharma. Dr. Waters received research support from Sanofi, Biogen, Roche, consulting fees/honoraria from Amneal, Adamas, Impel, Kyowa, Mitsubishi, Neurocrine, US World Meds, Acadia, Acorda. Dr. Espay received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Neurocrine, Impax/Amneal, Sunovion, Lundbeck, Osmotica Pharmaceutical, and US World Meds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from US World Meds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the Movement Disorders Society. Dr. Dupré received consultancy fees from Actelion Pharmaceuticals. Dr. Hassin-Baer received consulting fees from Actelion Pharmaceuticals Ltd., Abbvie Israel, Robotico Ltd., Medtronic Israel, Medison Pharma Israel. Dr. Fon received consulting fees from Inception Sciences. Dr. Alcalay received consultation fees from Biogen, Denali, Genzyme/Sanofi and Roche. Dr. Gan-Or received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali and Deerfield. No other disclosures were reported.
Funding Statement
Funding/Support
This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study protocols were approved by the relevant Institutional Review Boards and all patients signed informed consent before participating in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
